Search results
Results from the WOW.Com Content Network
Myostatin inhibitors are a class of drugs that work by blocking the effect of myostatin, which inhibits muscle growth. In animal models and limited human studies, myostatin inhibitors have increased muscle size. They are being developed to treat obesity, sarcopenia, muscular dystrophy, and other illnesses.
This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page.
Generally, drugs outlined within the ATC code M should be included in this category. Please see WP:PHARM:CAT for more information. Wikimedia Commons has media related to Musculoskeletal drugs .
Muscle atrophy is the loss of skeletal muscle mass. It can be caused by immobility, aging, malnutrition, medications, or a wide range of injuries or diseases that impact the musculoskeletal or nervous system. Muscle atrophy leads to muscle weakness and causes disability.
ATC code M01 Anti-inflammatory and antirheumatic products is a therapeutic subgroup of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products.
You can’t go far lately without seeing news and social media coverage of GLP-1 (glucagon-like peptide-1) receptor agonists like Ozempic®, Wegovy®, Mounjaro®, and Zepbound®.
There is no standard course of treatment to slow or stop the progression of the disease as of 2019. [1] sIBM patients do not reliably respond to anti-inflammatory, immunosuppressant, or immunomodulatory medications. [31] Most of disease management is supportive care. [1] Prevention of falls is an important consideration. [1]
These drugs aim to achieve adequate muscle relaxation for surgical procedures to prevent surgical trauma. [2] Vecuronium and pancuronium have an onset of 2 to 5 minutes in adults. [ 2 ] The time it takes to recover 25% of neuromuscular control after vecuronium and pancuronium therapy are 25 to 40 minutes and 60 to 80 minutes respectively.